Beranda › Miastenia Gravis › Arizona
Uji klinis Miastenia Gravis di Arizona
7 studi untuk Miastenia Gravis mencari peserta di lokasi di Arizona.
Kota di Arizona
Teks studi resmi (Bahasa Inggris)
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
- Mg0038 10104, Scottsdale
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07463521Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- Arizona Neuroscience Research, LLC, Phoenix
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT06463587A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
- Phoenix Children's Hospital, Phoenix
Menerima pesertaFase 2/3
Usia 2 hingga 17 · Semua jenis kelamin · Diperbarui 31 Jul 2026 · NCT05265273Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1017, Phoenix
- Site Number - 1025, Scottsdale
- Site Number - 1042, Tucson
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 30 Jul 2026 · NCT07039916A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Neuromuscular Research Center and Clinic, Paradise Valley
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 27 Jul 2026 · NCT04951622A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- HonorHealth Neurology - Bob Bové Neuroscience Institute, Scottsdale
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Jun 2026 · NCT06456580Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Scottsdale
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Feb 2026 · NCT04202341Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.